Ascendis Pharma A/S
ASND
302 hedge funds and large institutions have $13.8B invested in Ascendis Pharma A/S in 2025 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 121 increasing their positions, 91 reducing their positions, and 37 closing their positions.
211% more call options, than puts
Call options by funds: $189M | Put options by funds: $60.8M
68% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 37
33% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 91
9% more capital invested
Capital invested by funds: $12.7B → $13.8B (+$1.09B)
8% more funds holding
Funds holding: 279 → 302 (+23)
0.9% more ownership
Funds ownership: 103.53% → 104.43% (+0.9%)
29% less funds holding in top 10
Funds holding in top 10: 17 → 12 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$186M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$102M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$97.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$66.1M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$48.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$206M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$102M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$101M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$87.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$68.5M |
ASND Hedge Fund Activity: Q4 2025 in Review
302 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2025, worth a combined $13.8B — up 8.6% from $12.7B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new ASND positions and 37 closed out — a net gain of 25 holders — while 121 added to existing stakes and 91 trimmed.
The largest buyer was American Century Companies, adding an estimated $186M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $206M.
- 302 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2025, up from 279 in Q3 2025.
- Funds reported $13.8B of Ascendis Pharma A/S stock for Q4 2025, up 8.6% quarter-over-quarter.
- 62 funds opened new Ascendis Pharma A/S positions in Q4 2025 and 37 closed out, a net change of +25 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2025 was American Century Companies, an estimated $186M added.
- The largest Ascendis Pharma A/S seller in Q4 2025 was T. Rowe Price Investment Management, an estimated $206M sold.
Based on aggregated 13F filings for Q4 2025.